Cargando…

Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles

OBJECTIVES: To design oral controlled release (CR) hydrogel matrix tablets of etamsylate using various hydrophilic polymers. Additionally, to predict plasma concentration-time profiles of etamsylate released from different CR matrices. METHODS: Characterization of the in-vitro release rate was perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Masry, Soha M., Helmy, Sally A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783234/
https://www.ncbi.nlm.nih.gov/pubmed/33424262
http://dx.doi.org/10.1016/j.jsps.2020.10.016
_version_ 1783632072039989248
author El-Masry, Soha M.
Helmy, Sally A.
author_facet El-Masry, Soha M.
Helmy, Sally A.
author_sort El-Masry, Soha M.
collection PubMed
description OBJECTIVES: To design oral controlled release (CR) hydrogel matrix tablets of etamsylate using various hydrophilic polymers. Additionally, to predict plasma concentration-time profiles of etamsylate released from different CR matrices. METHODS: Characterization of the in-vitro release rate was performed by various model dependent and model independent approaches. A simple numerical convolution strategy was adopted to predict the in-vivo performance of all matrices from their in-vitro percent released data. The statistical analysis was conducted utilizing a student t-test and ANOVA. RESULTS: The release of etamsylate from all matrices showed a deviation from Fickian transport mechanism except; F2 followed Case II release whereas, F9 and F11 obeyed Fickian diffusion. CR hydrogel based-matrices (F4 and F11) demonstrated the maximum drug retardation and satisfied the USP release limits. Concentration–time profiles of etamsylate were predicted successfully from the in-vitro release data of all prepared matrices. Pharmacokinetic parameters of etamsylate CR hydrogel matrices were significantly changed with comparison to reference product except F1. CONCLUSION: The designed (F2-F11) matrices had the capability to extend the plasma level of etamsylate for an adequate time. However, F4 and F11 were considered the most ideal formulations for once daily application of etamsylate. The prediction of in-vivo pharmacokinetics of etamsylate was very useful to assess the rationality of the designed matrices for the practical application in humans.
format Online
Article
Text
id pubmed-7783234
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77832342021-01-08 Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles El-Masry, Soha M. Helmy, Sally A. Saudi Pharm J Original Article OBJECTIVES: To design oral controlled release (CR) hydrogel matrix tablets of etamsylate using various hydrophilic polymers. Additionally, to predict plasma concentration-time profiles of etamsylate released from different CR matrices. METHODS: Characterization of the in-vitro release rate was performed by various model dependent and model independent approaches. A simple numerical convolution strategy was adopted to predict the in-vivo performance of all matrices from their in-vitro percent released data. The statistical analysis was conducted utilizing a student t-test and ANOVA. RESULTS: The release of etamsylate from all matrices showed a deviation from Fickian transport mechanism except; F2 followed Case II release whereas, F9 and F11 obeyed Fickian diffusion. CR hydrogel based-matrices (F4 and F11) demonstrated the maximum drug retardation and satisfied the USP release limits. Concentration–time profiles of etamsylate were predicted successfully from the in-vitro release data of all prepared matrices. Pharmacokinetic parameters of etamsylate CR hydrogel matrices were significantly changed with comparison to reference product except F1. CONCLUSION: The designed (F2-F11) matrices had the capability to extend the plasma level of etamsylate for an adequate time. However, F4 and F11 were considered the most ideal formulations for once daily application of etamsylate. The prediction of in-vivo pharmacokinetics of etamsylate was very useful to assess the rationality of the designed matrices for the practical application in humans. Elsevier 2020-12 2020-11-06 /pmc/articles/PMC7783234/ /pubmed/33424262 http://dx.doi.org/10.1016/j.jsps.2020.10.016 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
El-Masry, Soha M.
Helmy, Sally A.
Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title_full Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title_fullStr Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title_full_unstemmed Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title_short Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of in-vivo plasma profiles
title_sort hydrogel-based matrices for controlled drug delivery of etamsylate: prediction of in-vivo plasma profiles
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783234/
https://www.ncbi.nlm.nih.gov/pubmed/33424262
http://dx.doi.org/10.1016/j.jsps.2020.10.016
work_keys_str_mv AT elmasrysoham hydrogelbasedmatricesforcontrolleddrugdeliveryofetamsylatepredictionofinvivoplasmaprofiles
AT helmysallya hydrogelbasedmatricesforcontrolleddrugdeliveryofetamsylatepredictionofinvivoplasmaprofiles